anti- ALDH5A1 antibody

Contáctenos para saber el precio
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
anti- ALDH5A1 antibody
category
Primary Antibodies
provider
FineTest
reference
FNab00297
tested applications
ELISA, WB, IHC
Description
Catalyzes one step in the degradation of the inhibitory neurotransmitter gamma-aminobutyric acid(GABA).
Documents del producto
Instrucciones
Data sheet
Product specifications
Category | Primary Antibodies |
Immunogen Target | aldehyde dehydrogenase 5 family, member A1 |
Host | Rabbit |
Reactivity | human,mouse,rat |
Recommended Dilution | WB: 1:500-1:5000; IHC: 1:20-1:200 |
Clonality | polyclonal |
Conjugation | Unconjugated |
Isotype | IgG |
Observed MW | 51 kDa |
Purity | ≥95% as determined by SDS-PAGE |
Purification | Immunogen affinity purified |
Size 1 | 100µg |
Form | liquid |
Tested Applications | ELISA, WB, IHC |
Storage | PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.) |
UniProt ID | P51649 |
Gene ID | 7915 |
Alias | ALDH5A1,SSADH |
Background | Antibody anti-ALDH5A1 |
Status | RUO |
Note | This product is for research use only. |
Descripción
ALDH5A1, also known as succinic semialdehyde dehydrogenase (SSADH), is a mitochondrial enzyme involved in the catabolism of gamma-aminobutyric acid (GABA), an important inhibitory neurotransmitter. ALDH5A1 catalyzes the oxidation of succinic semialdehyde (SSA) to succinate, a key intermediate in the tricarboxylic acid (TCA) cycle, linking GABA metabolism to cellular energy production. Mutations in ALDH5A1 result in succinic semialdehyde dehydrogenase deficiency, a rare autosomal recessive disorder that causes the accumulation of SSA and GABA, leading to neurological symptoms such as developmental delays, hypotonia, seizures, and ataxia. ALDH5A1 plays a crucial role in maintaining GABA homeostasis and preventing neurotoxicity. Its dysfunction highlights the importance of proper neurotransmitter balance and energy metabolism in neurological health. Therapies targeting ALDH5A1 function focus on reducing SSA accumulation and alleviating associated neurological impairments.
Related Products

Human ALDH5A1(Succinate-semialdehyde dehydrogenase, mitochondrial) ELISA Kit
Ver Producto
anti- ALDH5A1 antibody
Catalyzes one step in the degradation of the inhibitory neurotransmitter gamma-aminobutyric acid(GABA).
Ver Producto